Drug Target Equipment & Supplies
113 equipment items found
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
In the development of RA and other inflammatory types of arthritis, multiple factors contribute to disease processes to varying degrees in different patients. 14-3-3η is recognized as a new factor within this process and represents a rationale drug target for personalized medicine alongside its 14-3-3η companion biomarker portfolio described above. ...
by:PharmAI GmbH based inDresden, GERMANY
The technology behind PharmAI’s DiscoveryEngine allows for an unprecedented level of detail in the representation of drug-target complexes. Besides geometric comparison of binding sites based on local alignments, non-covalent interactions were included as they significantly improve the prediction of binding site similarities. Over many years, PharmAI ...
Manufactured by:Confo Therapeutics based inGhent/Zwijnaarde, BELGIUM
With its unique antibody-based technology, Confo Therapeutics aims to overcome the current limitations of GPCR drug discovery in order to fully realize the potential of GPCRs as drug ...
Manufactured by:G3T Therapeutics based inMidlothian, VIRGINIA (USA)
All drugs targeting cardiovascular disease currently on the market work by lowering cholesterol levels. G3T identified and genetically validated an entirely novel biological mechanism and potential drug target that treats both cardiovascular disease, as well as non-alcoholic fatty liver disease. ...
Manufactured by:Inoviem Scientific SAS based inIllkirch-Graffenstaden, FRANCE
Identify the mode of action of your compound with NPOT® technology; NPOT technology is a unique heterogeneous assembly method for conducting extensive identification of all proteins (together with their native structure) involved in drug-target ...
Distributed by:MoBiTec GmbH based inGoettingen, GERMANY
COVID-19 Research: Antiviral Drug Target ? The COVID-19 pandemic is caused by infection of SARS-CoV-2 or severe acute respiratory syndrome coronavirus 2, a positive-sense single-stranded RNA virus. The RNA dependent RNA polymerase (RdRp) is a key drug target for this deadly virus. ...
Manufactured by:Adrenomed AG based inBerlin, GERMANY
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody ...
Manufactured by:GENFIT based inLoos, FRANCE
Primary Biliary Cholangitis (PBC) is a chronic disease in which bile ducts in the liver are gradually destroyed.1 The damage to bile ducts can inhibit the liver’s ability to rid the body of toxins, and can lead to cirrhosis. Targeting PPAR receptors may result in a reduction of bile acid synthesis, improved detoxification of bile in the bile duct and anti-inflammatory ...
by:AdAlta Limited based inBundoora, AUSTRALIA
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to the drug target, CXCR4 and demonstrates anti-fibrotic effects in several models of fibrosis. This was initially called AD-114. ...
Manufactured by:EntroGen, Inc. based inWoodland Hills, CALIFORNIA (USA)
IDH1/2 mutations are linked to abnormal histone and DNA methylation which may cause altered stem cell differentiation and eventual tumorigenesis. The unique features of IDH1/2 mutations make them good biomarkers and promising drug targets. ...
Manufactured by:Biosensors International Group, Ltd. based inSingapore, SINGAPORE
BA9, an effective Cytostatic Limus Drug: Rapid 28 day BA9 transfer to the vessel wall achieved through enhanced high lipophilicity delivering: Greater Local Bioavailability. Targeted Drug Release. Local tissue warehousing allowing Sustained Tissue Release, with Therapeutic Effect up to 100 days12,13. Longer Half Life than other commonly used ...
Manufactured by:OPKO Health, Inc. based inMiami, FLORIDA (USA)
This strategy is unique and contrasts with established approaches which down-regulate protein production. This platform can lead to the discovery of new drugs to target relevant genes that regulate the optimal production of endogenous functional proteins. One of the leading applications of our AntagoNAT technology is OPK88001 which is designed for the treatment ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: ...
Manufactured by:Advanced Accelerator Applications SA based inRueil-Malmaison Cedex, FRANCE
AAA brand names for [18F]-choline (FCH). ...
by:Onegene Biotechnology based inSuwon, SOUTH KOREA
Onegene Biotechnology is pioneering multi-target therapeutics to create breakthrough medicines that will transform the lives of people with complex and chronic diseases. Onegene’s proprietary platform, UniStac®, allows rapid expansion of promising combinations of the targets into a single multi-target molecule with enzyme-mediated protein-protein conjugation technology while removing ...
Manufactured by:Kala Pharmaceuticals, Inc. based inArlington, MASSACHUSETTS (USA)
AMPPLIFY Drug Delivery Technology is designed to enhance penetration through the mucus barrier and deliver increased concentration of drug to the target ocular tissue. AMPPLIFY Drug Delivery Technology has been shown to improve delivery of loteprednol etabonate compared to traditional suspension eyedrops without ...
Manufactured by:Translumina GmbH based inHechingen, GERMANY
The Translumina Yukon Choice PC drug-eluting stent, coated with Rapamycin (Sirolimus) and the biodegradable component polylactide (PLA), has an excellent history of pre-clinical and long-term clinical ...
Manufactured by:Skyepharma Production SAS based inSaint-Quentin-Fallavier, FRANCE
Geoclock® is a validated tab in tab (press coated tablet) oral drug delivery technology that allows for timed release of active ingredient from the tablet (oral chronotherapy), independent of food or pH. Geoclock® can additionally be used for multiple pulse delivery of one or more drugs with pre-determined time intervals between the pulses, or to ...
Manufactured by:LVD Biotech based inSant Vicenç dels Horts, SPAIN
Our Drug-Eluting Technology (Transfertech) has been designed to guarantee the durability of the coating in the first navigation stage until reaching the injury. The balloon surface is covered with multiple and independent nano drops layers, providing a flexible coating that adapts to the balloon movement and ensures the release of the drug in the ...